Completed PHASE4 INTERVENTIONAL NCT00736034

The Efficacy of Phosphatidylserine-Omega3 in Elderly Subjects With Memory Impairment

A Single-Center, Open-Label Study to Assess the Efficacy of SharpPS™-Gold in Elderly Subjects With Memory Impairment

Sponsor: Enzymotec

Interventions Phosphatidylserine-Omega3 (SharpPS™-Gold)

Updated 5 times since 2017 Last updated: Mar 26, 2010 Started: Sep 30, 2008 Primary completion: Mar 31, 2009 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00736034, this PHASE4 trial focuses on Memory Impairment and remains completed. Sponsored by Enzymotec, it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Enzymotec

Data source: Enzymotec

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tel Aviv, Israel